Imugene’s VAXINIA Study: A Potential Game-Changer in Cancer Treatment

Imugene Ltd ((IUGNF)) announced an update on their ongoing clinical study.

Imugene Ltd is conducting a Phase I clinical study titled ‘A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).’ The study aims to evaluate the safety and tolerability of CF33-hNIS, an oncolytic virus, in treating advanced solid tumors, highlighting its potential significance in cancer therapy.

The study tests CF33-hNIS, a chimeric orthopoxvirus engineered to express the human sodium iodide symporter, administered either alone or with Pembrolizumab or modified FOLFOX. This intervention targets metastatic or advanced solid tumors, aiming to disrupt cancer cells.

This open-label, non-randomized study follows a sequential intervention model with no masking, focusing primarily on treatment. It assesses CF33-hNIS both as a standalone treatment and in combination with other therapies, exploring different administration routes.

The study began on March 22, 2022, with an estimated completion date of June 11, 2025. These timelines are crucial for tracking progress and anticipating results that could influence treatment options and market dynamics.

The update on this study could impact Imugene Ltd’s stock performance, as positive results may boost investor confidence and position the company favorably against competitors in the oncology sector. The ongoing recruitment and study updates are pivotal for stakeholders monitoring advancements in cancer treatment.

The study is currently ongoing, with further details available on the ClinicalTrials portal.